37 terminated. 37 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 37 | Terminated 37 |
| Phase 2 | 16 | Terminated 16 |
Follow Heredodegenerative Disorders, Nervous System: new trials by email Literature Review of Heredodegenerative Disorders, Nervous System trials Research Report on Heredodegenerative Disorders, Nervous System
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults Radiprodil with Carbamazepine, Radiprodil with Itraconazole - Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia | Phase 1 | Terminated | GRIN Therapeutics, Inc. | 30 | 2025-05-08 | 2025-11-21 |
| A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia Nomlabofusp, Placebo - Friedreich Ataxia | Phase 1 | Terminated | Larimar Therapeutics, Inc. | 18 | 2024-12-06 | 2026-07-10 |
| Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations NFS-02 Injection - Leber Hereditary Optic Neuropathy (LHON) | Phase 1 / Phase 2 | Terminated | Neurophth Therapeutics Inc | 11 | 2023-08-15 | 2024-09-20 |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer AC176 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Accutar Biotechnology Inc | 8 | 2023-02-22 | 2024-01-25 |
| A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors RGT-264 phosphate tablets - Advanced Solid Tumor | Phase 1 | Terminated | Regor Pharmaceuticals Inc. | 11 | 2023-02-15 | 2024-08-01 |
| A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) SBT101 Treatment - AMN, AMN Gene Mutation | Phase 1 / Phase 2 | Terminated | SwanBio Therapeutics, Inc. | 9 | 2022-11-17 | 2026-08-26 |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer AC176 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Accutar Biotechnology Inc | 28 | 2022-03-16 | 2025-02-13 |
| A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3 BIIB132, BIIB132-Matching Placebo - Spinocerebellar Ataxia Type 3 | Phase 1 | Terminated | Biogen | 8 | 2022-02-02 | 2023-08-04 |
| Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD Deutetrabenazine Oral Tablet [Austedo], Placebo oral tablet - Huntington Disease | Phase 1 | Terminated | Fundacion Huntington Puerto Rico | 36 | 2022-01-21 | 2025-02-27 |
| A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis AL2846 capsules - Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 22 | 2021-09-07 | 2024-03-21 |
| PF-07284892 in Participants With Advanced Solid Tumors PF-07284892, lorlatinib, binimetinib - Solid Tumor | Phase 1 | Terminated | Pfizer | 53 | 2021-03-17 | 2026-06-04 |
| Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477) REMD-477 - Hyperglycemia Drug Induced | Phase 1 | Terminated | Duke University | 1 | 2020-11-13 | 2022-11-08 |
| Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. CYH33 - Ovarian Cancer, Breast Cancer | Phase 1 | Terminated | Haihe Biopharma Co., Ltd. | 24 | 2020-09-28 | 2024-03-21 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease WVE-120101 - Huntington Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 27 | 2020-04-13 | 2022-02-09 |
| Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer Enzalutamide Liquid, Enzalutamide Capsule - Prostate Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2020-03-10 | 2021-05-10 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease WVE-120102 - Huntington Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 36 | 2019-09-24 | 2022-02-09 |
| Extension Study to Study PQ-110-001 (NCT03140969) QR-110 - Leber Congenital Amaurosis 10, Blindness | Phase 1 / Phase 2 | Terminated | Laboratoires Thea | 9 | 2019-05-13 | 2024-10-15 |
| Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer Exicorilant, Enzalutamide, Placebo - Metastatic Castration-Resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Corcept Therapeutics | 39 | 2018-02-20 | 2026-05-15 |
| Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease WVE-120101, Placebo - Huntington's Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 61 | 2017-07-17 | 2022-02-10 |
| Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease WVE-120102, Placebo - Huntington's Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 88 | 2017-07-17 | 2022-04-25 |
Showing 20 of 37. Sign in to see all of them.
Hereditary Sensory and Autonomic Neuropathies (10) · Huntington Disease (6) · Bulbo-Spinal Atrophy, X-Linked (4) · Breast Neoplasms (3) · Optic Atrophy, Hereditary, Leber (3) · Prostatic Neoplasms (3) · Adrenoleukodystrophy (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Motor Neuron Disease (2) · Mucopolysaccharidosis II (2) · Muscular Atrophy, Spinal (2) · Neoplasms (2) · Recurrence (2) · Spinal Muscular Atrophies of Childhood (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37) · Genetic Diseases, Inborn (37) · Nervous System Diseases (37) · Neurodegenerative Diseases (33) · Central Nervous System Diseases (18) · Neuromuscular Diseases (18) · Congenital Abnormalities (13) · Brain Diseases (12) · Nervous System Malformations (12) · Peripheral Nervous System Diseases (12) · Polyneuropathies (11) · Neoplasms (10) · Pathological Conditions, Signs and Symptoms (10) · Dyskinesias (9)
Cetuximab (3) · 4-phenylbutyric acid (2) · enzalutamide (2) · 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine (1) · 5-(2'-fluoroethyl)flumazenil (1) · Alpelisib (1) · Bevacizumab (1) · CYH33 (1) · Carbamazepine (1) · Disulfides (1) · Immunoglobulin G (1) · Infusions, Intravenous (1) · Itraconazole (1) · Miransertib (1) · N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide (1)
Wave Life Sciences USA, Inc. (4) · Accutar Biotechnology Inc (2) · Westat (2) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · Asana BioSciences (1) · Biogen (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chipscreen Biosciences, Ltd. (1) · Corcept Therapeutics (1) · Duke University (1) · Fundacion Huntington Puerto Rico (1) · GRIN Therapeutics, Inc. (1) · Genentech, Inc. (1) · Haihe Biopharma Co., Ltd. (1) · Johns Hopkins University (1)
United States (27) · Australia (8) · Canada (6) · China (6) · United Kingdom (6) · France (5) · Germany (5) · Denmark (4) · Poland (4) · Netherlands (3) · Spain (2) · Belgium (1) · Hong Kong (1) · Israel (1) · Italy (1)
Asana BioSciences (1) · Daniel Sessler, MD (1) · Frederick T Chin, PhD (1) · Fugen Li, PhD (1) · Grace Mann, PhD (1) · Harry T Whelan, MD (1) · Iris Chan, M.D., Ph.D. (1) · Joan Martinez, MD (1) · Michael H. Bloch, MD, MS (1)
PMID 29480210, PMID 32250312, PMID 33639990, PMID 34333820, PMID 35110415, PMID 36299240, PMID 37311055, PMID 37875771, PMID 40713644, PMID 41389341
N01NS42361 (2), 2015 (1), 2016 (1), 2017 (1), 2018 (1)